Research Paper Volume 16, Issue 6 pp 5050—5064

Omilancor mitigates the senescence of nucleus pulposus cells induced by DDP through targeting MAP2K6

Fang Yafeng1, *, , Shi Xinpeng1, *, , Wei Rong1, , Cui Guofeng1, ,

  • 1 Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China
* Equal contribution

Received: October 9, 2023       Accepted: January 17, 2024       Published: March 20, 2024
How to Cite

Copyright: © 2024 Yafeng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Purpose: This study explores the potential of Omilancor in treating Intervertebral Disc Degeneration (IDD) through MAP2K6 targeting.

Methods: We analyzed mRNA microarray datasets to pinpoint MAP2K6 as a key regulator implicated in IDD progression. Follow-up studies demonstrated that cisplatin (DDP) could prompt cellular senescence in vitro by upregulating MAP2K6 expression. Through molecular docking and other analyses, we identified Omilancor as a compound capable of binding to MAP2K6. This interaction effectively impeded the cellular senescence induced by DDP.

Results: We further showed that administration of Omilancor could significantly alleviate the degeneration of IVDs in annulus fibrosus puncture-induced rat model.

Conclusions: Omilancor shows promise as a treatment for IDD by targeting MAP2K6-mediated cellular senescence.


IDD: Intervertebral Disc Degeneration; DDP: cisplatin; LBP: low back pain; IVD: intervertebral disc; NP: nucleus pulposus; AF: annulus fibrosus; EP: endplates; ECM: extracellular matrix; MAP2K6: Mitogen-activated protein kinase 6.